FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to polymorph of 2-[4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)pyrazol-1-yl]ethanol, particularly to a new crystalline phosphate salt of 2-[4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)pyrazol-1-yl]ethanol.
EFFECT: preparing the pharmaceutical composition and using the new salt in treating cell growth abnormalities, such as cancer in mammals.
10 cl, 10 dwg, 6 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| C-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN CANCER TREATMENT | 2018 |
|
RU2769694C2 |
| CRYSTALLINE TOSYLATE SALT (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8-9-DIHYDRO-2H-PYRIDO[4,3,2-de]PHTHALAZIN-3(7H)-ONE | 2011 |
|
RU2598606C2 |
| TOSYLATE SALT OF TRANS-N-ISOBUTYL-3-FLUORO-3-[3-FLUORO-4-(PYRROLIDIN-1-YLMETHYL)PHENYL]CYCLOBUTANE CARBOXAMIDE | 2008 |
|
RU2451016C2 |
| NEW DERIVATIVES OF IMIDAZO [4,5-C] QUINOLINES AND IMIDAZO [4,5-C] [1,5] NAPHTHYRIDINES AS LRRK2 INHIBITORS | 2016 |
|
RU2722149C1 |
| NONHYGROSCOPIC CRYSTALLINE 5-[(Z)-(5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[(2S)-2-HYDROXY-3-MORPHOLIN-4-YLPROPYL]-2,4-DIMETHYL-1H-PYRROL-3-CARBOXAMIDE MALEATE SALT, PHARMACEUTICAL COMPOSITION AND METHOD FOR CANCER TREATMENT | 2004 |
|
RU2319702C2 |
| NOVEL CRYSTALLINE FORM OF TRIAZOLO(4,5-d)PYRIMIDINE | 2005 |
|
RU2418802C2 |
| NEW TRIAZOLOPYRASINE DERIVATIVES AND THEIR APPLICATION | 2013 |
|
RU2643361C2 |
| NEW CRYSTAL AND AMORPHOUS FORM OF TRYAZOL[4,5-d] PYRIMIDINE | 2001 |
|
RU2325391C2 |
| NEW IMIDAZO[4,5-c]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | 2018 |
|
RU2773516C2 |
| AMINOPYRAZINE COMPOUNDS WITH THE A2A ANTAGONIST PROPERTIES | 2015 |
|
RU2727805C2 |
